Results 31 to 40 of about 8,209 (210)

Safety and Efficacy of Upadacitinib for Atopic Dermatitis in Japan: Analysis of the 3-Year Phase 3 Rising Up Study

Dermatology and Therapy, 2023
Introduction Upadacitinib is an oral Janus kinase inhibitor approved in multiple countries for moderate-to-severe atopic dermatitis (AD). Here we present long-term data for up to 3 years of continuous upadacitinib treatment in Japanese patients with AD ...
Norito Katoh, Masanori Ikeda, Yukihiro Ohya, Hiroyuki Murota, Xiaofei Hu, John Liu, Hayato Niiyama, Takuya Sasaki, Eliza M. Raymundo, Hidehisa Saeki   +9 more
doaj   +1 more source

Association of Abatacept With Lower Mortality Risk Compared to Rituximab in Rheumatoid Arthritis–Associated Interstitial Lung Disease: An Emulated Target Trial

Arthritis &Rheumatology, EarlyView.
Objective The optimal treatment strategy for rheumatoid arthritis–associated interstitial lung disease (RA‐ILD) remains uncertain, and direct comparative data between biologics are limited. This study aimed to evaluate the effectiveness and safety of abatacept compared with rituximab in patients with RA‐ILD.
Po‐Cheng Shih, Shiow‐Ing Wang, Qing‐Wen Wang, James Cheng Chung Wei   +3 more
wiley   +1 more source

Upadacitinib [PDF]

pharma-kritik, 2020
Ein weiterer Januskinase-Hemmer, der bei der rheumatoiden Arthritis eingesetzt werden kann. Bisher vorliegende Vergleiche mit Placebo, Methotrexat und Adalimumab lassen eine gute Wirksamkeit der neuen Substanz annehmen; es sind aber erst wenig Langzeitdaten verfügbar.
openaire   +2 more sources

Upadacitinib for the treatment of concomitant psoriasis and atopic dermatitis: a case series

Journal of Dermatological Treatment, 2023
Purpose: The overlap of psoriasis and atopic dermatitis (AD) is rare and treating moderate-to-severe cases can be challenging. Conventional immune-suppressive drugs cannot be used long-term, and no biological drugs are currently approved for treating ...
Luigi Gargiulo, Luciano Ibba, Giulia Pavia, Jessica Avagliano, Andrea Cortese, Antonio Costanzo, Alessandra Narcisi   +6 more
doaj   +1 more source

Comparative Effects of Fedratinib and Upadacitinib on Renal Ischemia-Reperfusion Injury in Rat Models [PDF]

Renal ischemia-reperfusion injury (RIRI) is a severe condition that frequently occurs following kidney transplantation or surgical procedures affecting renal blood flow.
Hussein, Furqan Hashim, Mosawi, Najah R. Al   +1 more
core   +2 more sources

Utilization of data below the analytical limit of quantitation in pharmacokinetic analysis and modeling: promoting interdisciplinary debate [PDF]

, 2018
Traditionally, bioanalytical laboratories do not report actual concentrations for samples with results below the LOQ (BLQ) in pharmacokinetic studies.
Atholl Johnston, Autmizguine J, Beal S, Charlotte I S Barker, Chen X, Denti P, European Medicines Agency, Gopalakrishnan S, Hanno Evard, Ivo Leito, Jitmuang A, Joseph F Standing, Kalev Takkis, Karin Kipper, Keizer RJ, Klünder B, Koit Herodes, Lewis Couchman, Max Hecht, Ministry of Health Labour and Welfare, NordVal, Organisation for Economic Co-operation and Development, Pires de Mello CP, Rūta Veigure, US FDA, van der Laan LE, van Kesteren C, Worm AM   +27 more
core   +1 more source

Reshaping study design for faster extrapolation‐based drug approval in pediatric inflammatory bowel diseases: An ESPGHAN–NASPGHAN position paper

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Children with inflammatory bowel diseases (IBD) have limited access to the available advanced therapies, given the lengthy gap between adult and pediatric approval. We aimed to review key hurdles for pediatric trials and recommend practical solutions.
Dan Turner, Amit Assa, Mikkel Malham, Shira Yuval Bar‐Asher, Carla Rayan, Jeffrey S. Hyams, Holm H. Uhlig, Brad Pasternak, David C. Wilson, Hilary K. Michel, Lissy de Ridder, Eric Zuckerman, Marina Aloi, Peter Szitanyi, Marla C. Dubinsky, Anne M. Griffiths, Roberto Saldana, Javier Martín‐de‐Carpi, Eytan Wine, Richard K. Russell, Jeremy Adler, Joseph Picoraro   +21 more
wiley   +1 more source

Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials

Rheumatology and Therapy
Introduction This integrated analysis of the phase 2/3 and phase 3 SELECT trials describes the safety profile of upadacitinib, an oral Janus kinase inhibitor, for up to 5 years of exposure across psoriatic arthritis (PsA), ankylosing spondylitis (AS ...
Gerd R. Burmester, Jayne Stigler, Andrea Rubbert-Roth, Yoshiya Tanaka, Valderilio F. Azevedo, Derek Coombs, Ivan Lagunes, Ralph Lippe, Peter Wung, Lianne S. Gensler   +9 more
doaj   +1 more source

Growth analysis among adolescents with moderate-to-severe atopic dermatitis receiving upadacitinib in combination with topical corticosteroids in Japan: A case study series from a phase 3, randomized, controlled trial (Rising Up)

World Allergy Organization Journal, 2022
Background: Treatment options for adolescents with moderate-to-severe atopic dermatitis (AD) are limited. Oral corticosteroid therapies are used to treat children and adolescents with moderate-to-severe AD; however, long-term use is not recommended ...
Toshiaki Tanaka, MD, Takuya Sasaki, BA, Kimitoshi Ikeda, PhD, Jianzhong Liu, MD, Allan R. Tenorio, MD, Yukihiro Ohya, PhD   +5 more
doaj   +1 more source

Perioperative utilization of JAK inhibitors in Perianal Fistulizing Crohn's disease

JPGN Reports, EarlyView.
Abstract With the recent approval of small molecule drugs such as upadacitinib in adult inflammatory bowel disease (IBD), their utilization is becoming more common; however, there is limited data on perioperative risks or optimal timing of cessation and resumption to mitigate flares. Current recommendations suggest holding these medications for 14 days
Alexander Lyons, Lindsey Lawrence, Samantha Saul   +2 more
wiley   +1 more source